Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

2020 New England Journal of Medicine 1,930 citations

Abstract

Among 11 patients with relapsed or refractory CD19-positive cancers, a majority had a response to treatment with CAR-NK cells without the development of major toxic effects. (Funded by the M.D. Anderson Cancer Center CLL and Lymphoma Moonshot and the National Institutes of Health; ClinicalTrials.gov number, NCT03056339.).

Keywords

Chimeric antigen receptorCD19Natural killer T cellNatural killer cellCancer researchLymphokine-activated killer cellImmunologyCellBiologyAntigenInterleukin 21ImmunotherapyT cellImmune systemCytotoxic T cellIn vitroGenetics

Affiliated Institutions

Related Publications

Publication Info

Year
2020
Type
article
Volume
382
Issue
6
Pages
545-553
Citations
1930
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1930
OpenAlex

Cite This

Enli Liu, David Marín, Pinaki P. Banerjee et al. (2020). Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. New England Journal of Medicine , 382 (6) , 545-553. https://doi.org/10.1056/nejmoa1910607

Identifiers

DOI
10.1056/nejmoa1910607